Abstract
Hypertrophic obstructive cardiomyopathy (HOCM) affects approximately 1 in 500 people globally. The condition results in hypertrophy of the interventricular septum and thickening of the left ventricular wall. Surgical management to resect the thickened myocardium or septal alcohol ablation are currently considered the mainstay treatment option for HOCM refractory to pharmacological therapy. In this special report we aim to highlight the current landscape of septal mass reduction in HOCM. Next, we describe the evolving discipline of minimally invasive techniques for reducing outflow tract obstruction in patients with HOCM. We further consider future options and outline a possible percutaneous approach for septal myectomy with a novel device.
Author contributions
V Patel, M Parikh and U Ojha were equally involved in conception, drafting, and editing this manuscript. All authors gave final approval of the manuscript and agree to be accountable for all aspects of the work.
Acknowledgments
Illustrations were created using the image library from https://smart.servier.com/ and https://biorender.com/ - no specific permission is required at the time of publication.
Financial & competing interests disclosure
V Patel is the inventor of the novel myectomy device described in the manuscript and holds a patent on the product. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.